What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region

Dermatology

Volumn 216, Issue 2, 2008, Pages 137-151

  García Diez, Amaro ^a   Ferrandiz Foraster, Carlos ^d   Vanaclocha Sebastián, Francisco ^b   Lizán Tudela, Luis ^e,f   Badia Llach, Xavier ^e   Sellers Fernández, Guillermo ^c  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c Endocrinology and Cardiometabolic Care Busines Unit   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Health Outcomes Research Europe   (Spain)

^f IQVIA   (United States)

Author keywords

Portugal; Psoriasis epidemiology; Quality of life; Spain

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; PSORALEN; RETINOID; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL FEATURE; COMORBIDITY; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHOTOTHERAPY; PORTUGAL; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SPAIN; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PORTUGAL; PROGNOSIS; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 38549140078     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111511     Document Type: Article

References (62)

1. Raychaudhuri SP, Farber EM: The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-17.
2. Ferrandiz C, Bordas X, Garcia-Patos V, Puig S, Pujol R, Smandia A: Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001;15:20-23.
3. Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia JA: Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002;46:867-873.
4. Garcia-Doval I, Feal C, Roson E, de la Torre C, Abalde MT, Florez A, Cruces MJ: Inpatient dermatology: characteristics of patients and admissions in a Spanish hospital. J Eur Acad Dermatol Venereol 2002;16:334-338.
5. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M: Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-1075.
6. Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M: Clinical Efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled phase III trials. Part I. J Cutan Med Surg 2005;9:303-312.
7. Ferrandiz C: New horizons in the treatment of psoriasis. Med Clin 2004;123:659-660.
8. Schäer T: Epidemiology of psoriasis. Dermatology 2006;212:327-337.
9. Stein KR, Pearce DJ, Feldman SR: The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005;24:52-57.
10. EMEA: Guideline on clinical investigation of medicinal product indicated for the treatment of psoriasis. 2004. http://www.emea.eu.int/pdfs/human/ewp/ 245402en.pdf (accessed August 1, 2006).
11. Schiffner R, Landthaler M, Stolz W: Willingness-to-pay and time-trade-off: useful utilities in patients with psoriasis vulgaris? Dermatol Psychosom 2000;1:100-103.
12. Lewis VJ, Finlay AY: Two decades experience of the Psoriasis Disability Index. Dermatology 2005;210:261-268.
13. Finlay AY, Kelly SE: Psoriasis - An index of disability. Clin Exp Dermatol 1987;12:8-11.
14. Ferrándiz C, García-Díez A, Lizán TL, Bermúez-Rey L, Badía LX: Impacto de la psoriasis en la calidad de vida relacionada con la salud. Med Clin (Barc) 2007;128:325-329.
15. Jenner N, Campbell J, Plunkett A, Marks R: Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 2002;43:255-261.
16. Marchetti A, LaPensee K, An P: A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. Clin Ther 1998;20:851-869.
17. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, Clark AR: The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564-569.
18. Heenen M, Simonart T: Biological agents and psoriatic epidermis: what are we ultimately targeting? Dermatology 2006;212:321-323.
19. Stern RS, Beer JZ, Mills DK: Lack of consensus among experts on the choice of UV therapy for psoriasis. Arch Dermatol 1999;135:1187-1192.
20. van de Kerkhof PC: Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001;26:356-361.
21. Plunkett A, Marks R: A review of the epidemiology of psoriasis vulgaris in the community. Australas J Dermatol 1998;39:225-232.
22. Kundakci N, Tursen U, Babiker MO, Gurgey E: The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002;41:220-224.
23. Olsen AO, Grjibovski A, Magnus P, Tambs K, Harris JR: Psoriasis in Norway as observed in a population-based Norwegian twin panel. Br J Dermatol 2005;153:346-351.
24. Marino MG, Carboni I, De Felice C, Maurici M, Maccari F, Franco E: Risk factors for psoriasis: a retrospective study on 501 outpatients clinical records. Ann Ig 2004;16:753-758.
25. Kawada A, Tezuka T, Nakamizo Y, Kimura H, Nakagawa H, Ohkido M, Ozawa A, Ohkawara A, Kobayashi H, Harada S, Igarashi A: A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003;31:59-64.
26. Jullien D, Barker J: Genetics of psoriasis. J Eur Acad Dermatol Venereol 2006;20:42-51.
27. Millington GW: Genomic imprinting and dermatological disease. Clin Exp Dermatol 2006;31:681-688.
28. Karason A, Gudjonsson JE, Jonsson HH, Hauksson VB, Runarsdottir EH, Stefansson K, Valdimarsson H, Gulcher JR: Genetics of psoriasis in Iceland: evidence for linkage of subphenotypes to distinct loci. J Invest Dermatol 2005;124:1177-1185.
29. Pasic A, Grahovac B, Lipozencic J, Kastelan M, Kostovic K, Ceovic R: The genetics of psoriasis. Acta Dermatovenerol Croat 2004;12:18-25.
30. Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121-128.
31. Naldi L, Parazzini F, Brevi A, Peserico A, Veller Fornasa C, Grosso G, Rossi E, Marinaro P, Polenghi MM, Finzi A, et al: Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992;127:212-217.
32. Smith AE, Kassab JY, Rowland Payne CM, Beer WE: Bimodality in age of onset of psoriasis, in both patients and their relatives. Dermatology 1993;186:181-186.
33. Youn JI, Park BS, Park SB, Kim SD, Suh DH: Characterization of early and late onset psoriasis in the Korean population. J Dermatol 1999;26:647-652.
34. Swanbeck G, Inerot A, Martinsson T, Wahlstrom J, Enerback C, Enlund F, Yhr M: Age at onset and different types of psoriasis. Br J Dermatol 1995;133:768-773.
35. Henseler T, Christophers E: Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-456.
36. Brenner W, Gschnait F, Mayr WR: HLA B13, B17, B37 and Cw6 in psoriasis vulgaris: association with the age of onset. Arch Dermatol Res 1978;262:337-339.
37. Karvonen J: HL-A antigens in psoriasis with special reference to the clinical type, age of onset, exacerbations after respiratory infections and occurrence of arthritis. Ann Clin Res 1975;7:301-311.
38. Bell LM, Sedlack R, Beard CM, Perry HO, Michet CJ, Kurland LT: Incidence of psoriasis in Rochester, Minn, 1980-1983. Arch Dermatol 1991;127:1184-1187.
39. Kavli G, Forde OH, Arnesen E, Stenvold SE: Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed) 1985;291:999-1000.
40. Duffy DL, Spelman LS, Martin NG: Psoriasis in Australian twins. J Am Acad Dermatol 1993;29:428-434.
41. Chaput JC, Poynard T, Naveau S, Penso D, Durrmeyer O, Suplisson D: Psoriasis, alcohol, and liver disease. Br Med J (Clin Res Ed) 1985;291:25.
42. Braathen LR, Botten G, Bjerkedal T: Psoriatics in Norway: a questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption. Acta Derm Venereol Suppl (Stockh) 1989;142:9-12.
43. Poikolainen K, Reunala T, Karvonen J, Lauharanta J, Karkkainen P: Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ 1990;300:780-783.
44. Mills CM, Srivastava ED, Harvey IM, Swift GL, Newcombe RG, Holt PJ, Rhodes J: Smoking habits in psoriasis: a case control study. Br J Dermatol 1992;127:18-21.
45. Poikolainen K, Reunala T, Karvonen J: Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994;130:473-477.
46. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B: Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol 2004;18:27-36.
47. Finzi AF, Benelli C: A clinical survey of psoriasis in Italy: 1st AISP report. Interdisciplinary Association for the Study of Psoriasis. J Eur Acad Dermatol Venereol 1998;10:125-129.
48. Gaston L, Lassonde M, Bernier-Buzzanga J, Hodgins S, Crombez JC: Psoriasis and stress: a prospective study. J Am Acad Dermatol 1987;17:82-86.
49. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL: The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000;143:969-973.
50. Roenigk HH, Epstein E, Maibach HI: Skin manifestations of psoriasis and eczematous psoriasis: maturation;in Roenigk HH, Maibach HI (eds): Psoriasis. New York, Dekker, 1998, pp 3-12.
51. Christophers E, Mrowietz U: Psoriasis;in Freedberg IM, Eisen AZ, Wolff K, et al (eds): Dermatology in General Medicine. New York, McGraw-Hill, 1999, pp 495-521.
52. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D: Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004;151:594-599.
53. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284.
54. Efthimiou P, Markenson JA: Psoriatic arthritis; in Paget SA, Gibofsky A, Beary JF, Sculco TP (eds): Hospital for Special Surgery Manual of Rheumatology and Outpatient Orthopedic Disorders Diagnosis and Therapy. Philadelphia, Lippincott Williams & Wilkins, 2005.
55. Helliwell PS, Taylor WJ: Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005;64(suppl 2):ii3-ii8.
56. Veale DJ, FitzGerald O: Psoriatic arthritis - Pathogenesis and epidemiology. Clin Exp Rheumatol 2002;20:S27-S33.
57. Veale D, Rogers S, Fitzgerald O: Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133-138.
58. Kent G, al-Abadie M: The Psoriasis Disability Index - Further analyses. Clin Exp Dermatol 1993;18:414-416.
59. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W: Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol 2003;148:1153-1160.
60. Sampogna F, Gisondi P, Tabolli S, Abeni D: Impairment of sexual life in patients with psoriasis. Dermatology 2007;214:144-150.
61. Kulkarni AS, Balkrishnan R, Richmond D, Pearce DJ, Feldman SR: Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J Am Acad Dermatol 2005;52:27-31.
62. Esposito M, Saraceno R, Giunta A, Maccarone M, Cimenti S: An Italian study on psoriasis and depression. Dermatology 2006;212:123-127.